Chris Howerton
Stock Analyst at Jefferies
(2.47)
# 2,416
Out of 4,918 analysts
74
Total ratings
42.37%
Success rate
13.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $4.33 | +84.76% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $17.61 | +348.61% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.43 | +179.72% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $1 | $0.49 | +102.63% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.37 | +25,593.43% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $7.89 | +9,025.48% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.48 | -66.22% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $19.40 | -48.45% | 1 | Feb 8, 2023 | |
| MEIP MEI Pharma | Downgrades: Underperform | $8 → $2 | $4.87 | -58.93% | 3 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $11.08 | -0.72% | 3 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $70 → $40 | $22.95 | +74.29% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $34.38 | +77.45% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $103.02 | -12.64% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.19 | +186.40% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $126 | $1.31 | +9,518.32% | 1 | Dec 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.22 | +800.90% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $22.19 | +197.43% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $6.29 | +249.76% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.62 | +1,196.30% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $1.15 | +1,813.04% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.42 | +1,519.72% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $23.53 | -10.75% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $13.70 | +4,133.58% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.11 | +5,305.41% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $69.00 | -76.81% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $53.83 | -49.84% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $6.58 | +18,137.08% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $4.33
Upside: +84.76%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $17.61
Upside: +348.61%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.43
Upside: +179.72%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $1
Current: $0.49
Upside: +102.63%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.37
Upside: +25,593.43%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $7.89
Upside: +9,025.48%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.48
Upside: -66.22%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $19.40
Upside: -48.45%
MEI Pharma
Feb 8, 2023
Downgrades: Underperform
Price Target: $8 → $2
Current: $4.87
Upside: -58.93%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $11.08
Upside: -0.72%
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $22.95
Upside: +74.29%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $34.38
Upside: +77.45%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $103.02
Upside: -12.64%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.19
Upside: +186.40%
Dec 13, 2021
Maintains: Buy
Price Target: $101 → $126
Current: $1.31
Upside: +9,518.32%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $2.22
Upside: +800.90%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $22.19
Upside: +197.43%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $6.29
Upside: +249.76%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.62
Upside: +1,196.30%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $1.15
Upside: +1,813.04%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.42
Upside: +1,519.72%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $23.53
Upside: -10.75%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $13.70
Upside: +4,133.58%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.11
Upside: +5,305.41%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $69.00
Upside: -76.81%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $53.83
Upside: -49.84%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $6.58
Upside: +18,137.08%